Lattice Biologics Ltd
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstru… Read more
Lattice Biologics Ltd (LBLTF) - Total Liabilities
Latest total liabilities as of June 2021: $505.69K USD
Based on the latest financial reports, Lattice Biologics Ltd (LBLTF) has total liabilities worth $505.69K USD as of June 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lattice Biologics Ltd - Total Liabilities Trend (2000–2020)
This chart illustrates how Lattice Biologics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lattice Biologics Ltd Competitors by Total Liabilities
The table below lists competitors of Lattice Biologics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zonzia Media Inc
PINK:ZONX
|
USA | $4.05 Million |
|
AD4 Capital Corp.
V:ADJ-P
|
Canada | CA$42.60K |
Liability Composition Analysis (2000–2020)
This chart breaks down Lattice Biologics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lattice Biologics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lattice Biologics Ltd (2000–2020)
The table below shows the annual total liabilities of Lattice Biologics Ltd from 2000 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-09-30 | $9.42 Million | +9.69% |
| 2019-09-30 | $8.59 Million | +2.38% |
| 2018-09-30 | $8.39 Million | +8.80% |
| 2017-09-30 | $7.71 Million | -26.63% |
| 2016-09-30 | $10.51 Million | +6.19% |
| 2015-09-30 | $9.90 Million | +1931.20% |
| 2014-09-30 | $487.18K | +16.06% |
| 2013-09-30 | $419.77K | +74.24% |
| 2012-09-30 | $240.91K | -26.67% |
| 2011-09-30 | $328.55K | -91.49% |
| 2010-09-30 | $3.86 Million | -72.57% |
| 2009-09-30 | $14.08 Million | +9.90% |
| 2008-09-30 | $12.81 Million | -18.94% |
| 2007-09-30 | $15.81 Million | +1057.00% |
| 2006-09-30 | $1.37 Million | +73.40% |
| 2005-09-30 | $787.81K | +41.99% |
| 2004-09-30 | $554.82K | +445.99% |
| 2002-09-30 | $101.62K | +668.67% |
| 2001-09-30 | $13.22K | -81.22% |
| 2000-09-30 | $70.40K | -- |